An Open-Label, Single-Sequence Crossover, Drug-Drug Interaction Study to Characterize the Impact of the Cytochrome P450 3A Inhibitor Itraconazole on the Pharmacokinetics and Safety of Dazucorilant in Healthy, Adult Subjects

This study aims to answer how repeat doses of itraconazole impact the pharmacokinetics, safety, and tolerability of single doses of dazucorilant in healthy adults.
Participants in this study will complete screening assessments within 28 days before the first dose of study drug. Those participants who can participate will be admitted to the clinical pharmacology center (CPC) and complete pretreatment tests. Those participants will stay at the CPC for the duration of the study. On Days 1 and 8, each participant will receive a single oral dose of dazucorilant 300 mg, after eating. On Days 5-11, all participants will receive once daily, oral doses of itraconazole 200 mg, after eating. Blood and safety assessments will continue for 96-hours after dosing on Day 1 and Day 8. Participants will leave the CPC following completion of all procedures on Day 12.
Participants will return to the CPC for a final visit 7 (±1) days after their final dose of study medication.

开始日期2024-05-31

申办/合作机构

Corcept Therapeutics, Inc.

NCT06108219 / Recruiting临床2期

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH)

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Miricorilant in Adult Patients with Nonalcoholic Steatohepatitis (MONARCH)

开始日期2023-10-25

申办/合作机构

Corcept Therapeutics, Inc.

NCT06099769 / Recruiting临床2期IIT

A RANDOMIZED, PHASE II STUDY OF ENZALUTAMIDE, ENZALUTAMIDE WITH MIFEPRISTONE, and TREATMENT OF PHYSICIAN'S CHOICE IN PATIENTS WITH AR+ METASTATIC TRIPLE-NEGATIVE OR ER-LOW BREAST CANCER

The researchers are doing this study to find out if the study drug, enzalutamide, alone or combined with the study drug, mifepristone, is effective in treating advanced or metastatic androgen receptor-positive (AR+) triple negative breast cancer (TNBC) or estrogen receptor-low breast cancer (ER-low BC), and whether these study treatments work as well as standard chemotherapy with carboplatin, paclitaxel, capecitabine, or eribulin.

开始日期2023-10-18

申办/合作机构

Memorial Sloan Kettering Cancer Center

[+3]

100 项与 Corcept Therapeutics, Inc. 相关的临床结果

登录后查看更多信息

0 项与 Corcept Therapeutics, Inc. 相关的专利（医药）

登录后查看更多信息

项与 Corcept Therapeutics, Inc. 相关的文献（医药）

2024-07-01·BMJ Open

Study protocol for a prospective, multicentre study of hypercortisolism in patients with difficult-to-control type 2 diabetes (CATALYST): prevalence and treatment with mifepristone

Article

作者: Findling, James W ; Blonde, Lawrence ; Auchus, Richard J ; DeFronzo, Ralph A ; Frias, Juan P ; Buse, John B ; Fonseca, Vivian A ; Einhorn, Daniel ; Bancos, Irina ; Handelsman, Yehuda ; Busch, Robert S ; Rosenstock, Julio ; Tudor, Iulia Cristina ; Hamidi, Oksana ; Moraitis, Andreas G ; Pratley, Richard E

Introduction:

Even with recent treatment advances, type 2 diabetes (T2D) remains poorly controlled for many patients, despite the best efforts to adhere to therapies and lifestyle modifications. Although estimates vary, studies indicate that in >10% of individuals with difficult-to-control T2D, hypercortisolism may be an underlying contributing cause. To better understand the prevalence of hypercortisolism and the impact of its treatment on T2D and associated comorbidities, we describe the two-part Hyper c ortisolism in P at ients with Difficult to Control Type 2 Di a betes Despite Receiving Standard-of-Care Therapies: Preva l ence and Treatment with Korl y m ® (Mifepri st one) (CATALYST) trial.

Methods and analysis:

In part 1, approximately 1000 participants with difficult-to-control T2D (haemoglobin A1c (HbA1c) 7.5%–11.5% despite multiple therapies) are screened with a 1 mg dexamethasone suppression test (DST). Those with post-DST cortisol >1.8 µg/dL and dexamethasone level ≥140 ng/dL are identified to have hypercortisolism (part 1 primary endpoint), have morning adrenocorticotropic hormone (ACTH) and dehydroepiandrosterone sulfate (DHEAS) measured and undergo a non-contrast adrenal CT scan. Those requiring evaluation for elevated ACTH are referred for care outside the study; those with ACTH and DHEAS in the range may advance to part 2, a randomised, double-blind, placebo-controlled trial to evaluate the impact of treating hypercortisolism with the competitive glucocorticoid receptor antagonist mifepristone (Korlym ® ). Participants are randomised 2:1 to mifepristone or placebo for 24 weeks, stratified by the presence/absence of an abnormal adrenal CT scan. Mifepristone is dosed at 300 mg once daily for 4 weeks, then 600 mg daily based on tolerability and clinical improvement, with an option to increase to 900 mg. The primary endpoint of part 2 assesses changes in HbA1c in participants with hypercortisolism with or without abnormal adrenal CT scan. Secondary endpoints include changes in antidiabetes medications, cortisol-related comorbidities and quality of life.

Ethics and dissemination:

The study has been approved by Cleveland Clinic IRB (Cleveland, Ohio, USA) and Advarra IRB (Columbia, Maryland, USA). Findings will be presented at scientific meetings and published in peer-reviewed journals.

Trial registration number:

NCT05772169 .

2024-01-01·Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists

Relacorilant, a Selective Glucocorticoid Receptor Modulator in Development for the Treatment of Patients With Cushing Syndrome, Does Not Cause Prolongation of the Cardiac QT Interval

Article

作者: Custodio, Joseph M ; Kearney, Tara ; Donaldson, Kirsteen ; Pivonello, Rosario ; Feelders, Richard A ; Stigliano, Antonio ; Giordano, Roberta ; Darpo, Borje ; Lardo, Pina ; Ghigo, Ezio ; Mariash, Cary N ; Xue, Hongqi ; Mezősi, Emese ; Donegan, Diane M ; Hand, Austin L ; Moraitis, Andreas G

OBJECTIVE:

To assess the effect of relacorilant, a selective glucocorticoid receptor modulator under investigation for the treatment of patients with endogenous hypercortisolism (Cushing syndrome [CS]), on the heart rate-corrected QT interval (QTc).

METHODS:

Three clinical studies of relacorilant were included: (1) a first-in-human, randomized, placebo-controlled, ascending-dose (up to 500 mg of relacorilant) study in healthy volunteers; (2) a phase 1 placebo- and positive-controlled thorough QTc (TQT) study of 400 and 800 mg of relacorilant in healthy volunteers; and (3) a phase 2, open-label study of up to 400 mg of relacorilant administered daily for up to 16 weeks in patients with CS. Electrocardiogram recordings were taken, and QTc change from baseline (ΔQTc) was calculated. The association of plasma relacorilant concentration with the effect on QTc in healthy volunteers was assessed using linear mixed-effects modeling.

RESULTS:

Across all studies, no notable changes in the electrocardiogram parameters were observed. At all time points and with all doses of relacorilant, including supratherapeutic doses, ΔQTc was small, generally negative, and, in the placebo-controlled studies, similar to placebo. In the TQT study, placebo-corrected ΔQTc with relacorilant was small and negative, whereas placebo-corrected ΔQTc with moxifloxacin positive control showed rapid QTc prolongation. These results constituted a negative TQT study. The model-estimated slopes of the concentration-QTc relationship were slightly negative, excluding an association of relacorilant with prolonged QTc.

CONCLUSION:

At all doses studied, relacorilant consistently demonstrated a lack of QTc prolongation in healthy volunteers and patients with CS, including in the TQT study. Ongoing phase 3 studies will help further establish the overall benefit-risk profile of relacorilant.

2023-10-20·Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Relacorilant + Nab-Paclitaxel in Patients With Recurrent, Platinum-Resistant Ovarian Cancer: A Three-Arm, Randomized, Controlled, Open-Label Phase II Study.

Article

作者: Colombo, Nicoletta ; Matulonis, Ursula A ; Van Gorp, Toon ; Grisham, Rachel N ; Greenstein, Andrew E ; Lorusso, Domenica ; Fleming, Gini F ; Tudor, Iulia C ; Nguyen, Dorothy D ; Olawaiye, Alexander B ; Custodio, Joseph M ; Oaknin, Ana ; Pashova, Hristina I

PURPOSE:

Despite therapeutic advances, outcomes for patients with platinum-resistant/refractory ovarian cancer remain poor. Selective glucocorticoid receptor modulation with relacorilant may restore chemosensitivity and enhance chemotherapy efficacy.

METHODS:

This three-arm, randomized, controlled, open-label phase II study (ClinicalTrials.gov identifier: NCT03776812) enrolled women with recurrent, platinum-resistant/refractory, high-grade serous or endometrioid epithelial ovarian, primary peritoneal, or fallopian tube cancer, or ovarian carcinosarcoma treated with ≤4 prior chemotherapeutic regimens. Patients were randomly assigned 1:1:1 to (1) nab-paclitaxel (80 mg/m²) + intermittent relacorilant (150 mg the day before, of, and after nab-paclitaxel); (2) nab-paclitaxel (80 mg/m²) + continuous relacorilant (100 mg once daily); or (3) nab-paclitaxel monotherapy (100 mg/m²). Nab-paclitaxel was administered on days 1, 8, and 15 of each 28-day cycle. The primary end point was progression-free survival (PFS) by investigator assessment; objective response rate (ORR), duration of response (DOR), overall survival (OS), and safety were secondary end points.

RESULTS:

A total of 178 women were randomly assigned. Intermittent relacorilant + nab-paclitaxel improved PFS (hazard ratio [HR], 0.66; log-rank test P = .038; median follow-up, 11.1 months) and DOR (HR, 0.36; P = .006) versus nab-paclitaxel monotherapy, while ORR was similar across arms. At the preplanned OS analysis (median follow-up, 22.5 months), the OS HR was 0.67 (P = .066) for the intermittent arm versus nab-paclitaxel monotherapy. Continuous relacorilant + nab-paclitaxel showed numerically improved median PFS but did not result in significant improvement over nab-paclitaxel monotherapy. Adverse events were comparable across study arms, with neutropenia, anemia, peripheral neuropathy, and fatigue/asthenia being the most common grade ≥3 adverse events.

CONCLUSION:

Intermittent relacorilant + nab-paclitaxel improved PFS, DOR, and OS compared with nab-paclitaxel monotherapy. On the basis of protocol-prespecified Hochberg step-up multiplicity adjustment, the primary end point did not reach statistical significance (P < .025). A phase III evaluation of this regimen is underway (ClinicalTrials.gov identifier: NCT05257408).

项与 Corcept Therapeutics, Inc. 相关的新闻（医药）

2024-10-31

·EndPoints

Corcept misses primary endpoint in supportive Cushing's syndrome study

Corcept Therapeutics announced Wednesday that its experimental treatment for Cushing’s syndrome missed the primary endpoint in a Phase 3 trial intended to support its FDA submission. While patients with hypertension who received relacorilant in the GRADIENT trial saw statistically significant improvements in mean systolic blood pressure from baseline over 22 weeks, the difference between relacorilant and placebo patients was not statistically significant. Corcept’s stock $CORT was down 7% in premarket trading Thursday. Relacorilant did meet a handful of secondary endpoints in GRADIENT, including hyperglycemia and body weight. Patients in this study had a type of Cushing’s syndrome caused by an adrenal adenoma or adrenal hyperplasia, CEO Joseph Belanoff said during its third-quarter results call with investors. Cushing’s syndrome occurs when there is too much cortisol in the body, putting patients at risk for a range of symptoms from weight gain to high blood pressure. The company previously reported that relacorilant met its primary endpoint in a pivotal study called GRACE, showing that patients who remained on the drug after an initial open-label phase maintained improvements compared to those who got placebo and saw their symptoms worsen, Corcept said. “We’re very confident with submitting an NDA based upon the GRADIENT data, but it’s not just the GRADIENT data,” Corcept’s chief development officer Bill Guyer told investors, according to an AlphaSense transcript. “GRADIENT, from its inception, was always designed to be supportive of GRACE, and GRACE was always going to be our pivotal study. And that’s our agreement with the FDA.” The company also touted that relacorilant was well-tolerated in GRADIENT, with no sign of side effects caused by other Cushing’s treatments, including hypokalemia (low potassium levels), endometrial hypertrophy (thickening of the uterine lining) or related vaginal bleeding, and others. Corcept lost a patent fight with Teva earlier this year over its currently marketed Cushing’s syndrome drug Korlym. On the investor call, Corcept’s endocrinology president Sean Maduck said relacorilant “is going to be even better” than Korlym. “It doesn’t have the off-target progesterone effects that we see with Korlym,” Maduck said.

临床3期临床结果申请上市

2024-10-23

·BioSpace

Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report third quarter financial results and provide a corporate update on October 30, 2024. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Conference Call Information Participants must register in advance of the conference call by clicking here . Upon registering, each participant will receive a dial-in number, and a unique access PIN. Each access PIN will accommodate one caller. Additionally, a listen-only webcast will be available by clicking here . A replay of the call will be available on the Investors / Events tab of Corcept.com. About Corcept Therapeutics For over 25 years, Corcept’s focus on cortisol modulation and its potential to treat patients with a wide variety of serious disorders has led to the discovery of more than 1,000 proprietary selective cortisol modulators. Corcept is conducting advanced clinical trials in patients with hypercortisolism, solid tumors, amyotrophic lateral sclerosis (ALS) and liver disease. In February 2012, the company introduced Korlym ® , the first medication approved by the U.S. Food and Drug Administration for the treatment of patients with Cushing’s syndrome. Corcept is headquartered in Redwood City, California. For more information, visit Corcept.com. Contacts Investor inquiries: ir@corcept.com Media inquiries: communications@corcept.com

上市批准财报

2024-10-04

·PRNewswire

Top Companies, Marketers, CEOs, Products, and Initiatives Were Celebrated During Trailblazer Gala on October 1st

NEW YORK, Oct. 4, 2024 /PRNewswire/ -- On Tuesday night, October 1st, at a gala event held at Gotham Hall in New York City, PM360 announced the winners of its 16th annual Trailblazer Awards. In total, PM360, a leading life sciences marketing industry trade publication, recognized 46 gold and 19 silver winners across eight overall categories: Companies of the Year, CEOs of the Year, Products of the Year, Marketer of the Year, Marketing Team of the Year, Lifetime Achievement, Brand Champions, and Initiatives. "We are thrilled to celebrate this industry's top professionals who are hard at work to improve patients' lives. It's our responsibility and our privilege to celebrate the accomplishments and innovation of these incredible people and companies as they drive the world of healthcare forward," says Anna Stashower, CEO and Publisher of PM360. "The Trailblazer winners are changemakers for a variety of conditions, including postpartum depression, lower respiratory tract disease (LRTD), obesity, cortisol dysregulation, epilepsy, and so many more disease areas. We were blown away by the ground-breaking contributions that they have made and the progress they've driven in ensuring access to much-needed medications." The over 450 attendees were treated to more than just an award ceremony. Actress and comedian Caroline Rhea kept the audience laughing as the emcee and DJ kept the dance party going until midnight. Each of the winners were judged and selected by the PM360 Editorial Advisory Board, a cross section of experts from across the industry. The judges are asked to evaluate the following criteria for each category: Company of Year (innovation, talent development, and social responsibility); Brand Champions (innovation, leadership, communication, analytical, and organizational skills); Initiatives (content, format, success in reaching targeted audience, and overall quality); Marketer of the Year (the individual who best exemplifies the most insightful, forward-thinking, and transformative marketing ideas and actions in the industry); Marketing Team (the team who best exemplifies those same qualities); Products of the Year (innovation in treating patients, the uniqueness of the branding strategy, and their ultimate and contribution to the overall healthcare system); CEOs of the Year (ability to thrive in all aspects of leadership including establishing a company culture, displaying a unique vision for their company, and earning respect from industry colleagues due to their morals, reputation, and character); and Lifetime Achievement (an industry veteran who has transformed the business through leadership, wide-ranging influence, and original contributions.) This year's Lifetime Achievement Award recipient is Adam Schechter, Chairman and CEO of Labcorp. Prior to this role and over his nearly 40-year career, Schechter held a variety of executive, senior, global and U.S.-focused leadership positions at Merck & Co., Inc., spanning sales, marketing, managed markets as well as business and product development. From 2010 to 2019, he served as Executive Vice President and President of Merck's Global Human and Health Division, leading the company's worldwide pharmaceutical and vaccine business, and serving as a member of Merck's Executive Committee. He has made substantial efforts to support the industry and community, with current leadership roles as Board Vice-Chair at the American Clinical Laboratory Association (ACLA), Executive Board Member of the National Alliance for Hispanic Health, and Board Member at Water.org, and DaVita Inc. He has also served on the Boards of the European Federation of Pharmaceutical Industries and Associations (EFPIA), where he led the Policy and Access Committee, the Healthcare Leadership Council and the Merial Animal Health Company. "Adam Schechter is a global business leader who spent an illustrious career holding senior executive roles and board seats in healthcare industry-leading companies. This diversified his already broad expertise in fields from vaccines to pharmaceuticals and marketing to product development, into a pillar of knowledge," said Anna Stashower, CEO and Publisher of PM360. "His work with LabCorp and other frontrunning organizations, as well as his dedication to world-changing initiatives in areas such as clean water, equal healthcare, and animal health, are all worthy of our Lifetime Achievement Award." Some of the other big winners include Sumitomo Pharma America, Inc. as this year's Pharmaceutical/Biotech Company of the Year, while embecta was named the Medical Device/Diagnostics Company of the Year and Neurocrine Biosciences, Inc. took home Specialty Pharma Company of the Year. Additionally, Elevate Healthcare was named the Advertising Agency of the Year and GoodRx was given the honor of Supplier/Vendor of the Year. In addition, Ivan Tornos, President and CEO of Zimmer Biomet, was named the Life Sciences Manufacturer CEO of the Year while Judy Capano, Managing Partner and CEO of Calcium+Company, was named the Advertising Agency or Supplier/Vendor CEO of the Year. As for the Brand of the Year, that honor went to Wegovy®. PM360 will publish profiles of this year's Trailblazer winners in its November issue and on its website. This year's PM360 Trailblazer winners include: LIFETIME ACHIEVEMENT AWARD RECIPIENT Adam Schechter, CEO & President (Labcorp) COMPANY OF THE YEAR: ADVERTISING AGENCY Elevate Healthcare COMPANY OF THE YEAR: MEDICAL DEVICE/DIAGNOSTICS embecta COMPANY OF THE YEAR: PHARMACEUTICAL/BIOTECH Sumitomo Pharma America, Inc. COMPANY OF THE YEAR: SPECIALTY PHARMA/BIOTECH Neurocrine Biosciences, Inc. COMPANY OF THE YEAR: SUPPLIER/VENDOR GoodRx ADVERTISING AGENCY OR SUPPLIER/VENDOR CEO OF THE YEAR Judy Capano, Managing Partner and CEO (Calcium+Company) LIFE SCIENCES MANUFACTURER CEO OF THE YEAR Ivan Tornos, President and Chief Executive (Zimmer Biomet) MARKETER OF THE YEAR Milana Fomin, Director Patient Marketing (Replimune) MARKETING TEAM OF THE YEAR SILVER WINNER XDEMVY Consumer Marketing Team (Tarsus Pharmaceuticals) MARKETING TEAM OF THE YEAR GOLD WINNER Corcept Therapeutics Team (Corcept Therapeutics) BRAND OF THE YEAR Wegovy (ConcentricLife) MOST INNOVATIVE NEW PRODUCT AREXVY Respiratory Syncytial Virus Vaccine, Adjuvanted (Razorfish Health and GSK) PRODUCT LAUNCH OF THE YEAR ZURZUVAE® (zuranolone) CIV (Sage Therapeutics and Biogen supported by Weber Shandwick and AbelsonTaylor) BRAND CHAMPION AWARD WINNERS Autoimmune/Rheumatology: Wakim Andre, Head of Marketing, North America (Biocon Biologics) Cardiology: Lali Lobzhanidze, Executive Director, Senior Marketing Strategist, Integrated Marketing (Novartis Pharmaceuticals) Dermatology: Jennifer Novak, Director, Consumer Digital Marketing, (Sanofi) Diabetes/Metabolic Disorders: Ginny Blocki, SVP, Global Marketing & Product Management, (embecta) HCP Engagement: Mayte Cabrera-Dorian, Executive Director, Novartis Patient Support - RLT (Novartis) Hematology/Oncology: Jennifer Monahan, Associate Director Consumer Marketing (Regeneron) Infectious Disease/Vaccine Development: Jackie Messinger, US Head of Marketing Respiratory (Moderna) Innovation/Digital Strategy: Jennifer Spevak, Director, U.S. Vaccines Market Development, Vaccine Portfolio Adherence, Pfizer Men's Health: Katie Lewandroski, Executive Director, Oncology Marketing Lead (Sumitomo Pharma America, Inc.) Ophthalmology/Optometry: Liz Tempesta, Senior Director, Consumer Marketing, Eye Care Division (Viatris) OTC Marketer: Vicky Louit, Director of Medical Marketing, Eucerin® and Aquaphor (Beiersdorf) Patient Engagement: Christine Szymanski, Consumer Strategy Lead, Obesity Marketing, (Novo Nordisk) Rare Diseases: Bryan Burkauskas, Director, US Oncology Marketing WELIREG (Merck) Respiratory: Marc Russo, Associate Director, Interstitial Lung Disease Marketing, (Boehringer Ingelheim Pharmaceuticals, Inc.) Women's Health: Mellisa Hunh, VP Myfembree Marketing Lead (Sumitomo Pharma America, Inc.) INITIATIVE WINNERS APP/DIGITAL SOLUTION OR SUITE SILVER WINNER NovoCare® Cost and Coverage (Novo Nordisk and Avalere Health) APP/DIGITAL SOLUTION OR SUITE GOLD WINNER Don't Sweat Inventory Management (Accord Biopharma, Inc. and Asentech, LLC) ARTIFICIAL INTELLIGENCE/DATA ANALYTICS INITIATIVE SILVER WINNER Advancing Care: Harnessing AI to Empower the Hard-to-Reach Patient Audience (argenx, Avalere Health and DxCheck) ARTIFICIAL INTELLIGENCE/DATA ANALYTICS INITIATIVE GOLD WINNER LOQTORZI DTP + HCP (Cluep, with Confideo Media for Coherus Biosciences) CONSUMER WEBSITE/ONLINE INITIATIVE SILVER WINNER "Dad Genes" (Johnson & Johnson Innovative Medicine and 21GRAMS, part of Real Chemistry) CONSUMER WEBSITE/ONLINE INITIATIVE GOLD WINNER DUPIXENT Eczema Skin Gallery Tool (Sanofi, Regeneron Pharmaceuticals, Inc. and EVERSANA INTOUCH) DIRECT-TO-CONSUMER CAMPAIGN SILVER WINNER The Season (Weber Shandwick and Sanofi) DIRECT-TO-CONSUMER CAMPAIGN GOLD WINNER KNOW PLAN GO (FCB Health New York, an IPG Health Company, Real Chemistry, & Starpower, part of Real Chemistry) DIRECT-TO-PATIENT CAMPAIGN SILVER WINNER Say Yep to VYEPTI (Lundbeck and EVERSANA INTOUCH) DIRECT-TO-PATIENT CAMPAIGN GOLD WINNER Life without compromise. (BioCryst Pharmaceuticals and Agency: Inizio Evoke Drive) HCP EDUCATION SILVER WINNER APDS Awareness: Educating Healthcare Professionals for Better Identification of Patients with the Ultra-Rare Disease (Equals 5, Rare Expertise, and Pharming Group N.V.) HCP EDUCATION GOLD WINNER SPEVIGO Branded Immersive Presentation (Confideo Labs for Boehringer Ingelheim) INTERACTIVE/IMMERSIVE MARKETING PROGRAM SILVER WINNER The CRx Experience Center (ConnectiveRx) INTERACTIVE/IMMERSIVE MARKETING PROGRAM GOLD WINNER Vertex Pharmaceuticals: Helping an Underserved Community Uncover a Deeper Diagnosis (Spectrum Science) OTC SILVER WINNER Reckitt Mucinex Flip the Script inOffice Provider Campaign (InStep Health and Reckitt Mucinex) OTC GOLD WINNER Eucerin® Face Immersive Hydration Launch (Deerfield Agency) PATIENT/CONSUMER EDUCATION SILVER WINNER Take Care of Your Mental Elf (Spectrum Science) PATIENT/CONSUMER EDUCATION GOLD WINNER VMS OneVoice — Re-imagining the Ideal Patient Experience (VMS BioMarketing) PERSISTENCE/ADHERENCE PROGRAM SILVER WINNER Transforming the Customer Experience in Rare Disease to Drive Adherence (Inizio Engage) PERSISTENCE/ADHERENCE PROGRAM GOLD WINNER Keeping Eliquis Front and Center Among Prescribers and Patients (BMS/Pfizer and ConnectiveRx) PODCASTS SILVER WINNER Untold Stories: Life with Myasthenia Gravis (argenx, Avalere Health, iHeartRadio, and Ruby by iHeartMedia) PODCASTS GOLD WINNER Swell Conversations: A Promotional HAE Series (Pharming and Precision AQ) PROFESSIONAL CAMPAIGN SILVER WINNER Reimagine Survival (Biolumina and Takeda Oncology) PROFESSIONAL CAMPAIGN GOLD WINNER VNS Therapy is a life-changer (LivaNova USA, Inc. and Elevate Healthcare) SALES AID SILVER WINNER It's Time to Rescue Rescue Unbranded HCP Campaign (AstraZeneca and VML Health) SALES AID GOLD WINNER I'm Just a Script: An Rx's Journey from Prescriber to Patient (Xavier Creative House and Johnson & Johnson) SELF-PROMOTION/CORPORATE CAMPAIGN SILVER WINNER Self ProMoletion Campaign (SFC Group) SELF-PROMOTION/CORPORATE CAMPAIGN GOLD WINNER Challenge Accepted (Elevate Healthcare) SOCIAL MEDIA CAMPAIGN SILVER WINNER Psoriasis Empathetic Language Campaign (dna Communications + Dermavant Sciences, Inc.) SOCIAL MEDIA CAMPAIGN GOLD WINNER Moderna: CMVictory (Spectrum Science) UNBRANDED CAMPAIGN SILVER WINNER Live With COPD (Sanofi, Regeneron Pharmaceuticals, Inc. and EVERSANA INTOUCH) UNBRANDED CAMPAIGN GOLD WINNER Know ESR1 (Menarini Stemline, Biolumina, and Coppola Photography) VIDEO/TV CAMPAIGN SILVER WINNER Say Yep to VYEPTI (Lundbeck and EVERSANA INTOUCH) VIDEO/TV CAMPAIGN GOLD WINNER Believe On (Novo Nordisk and ConcentricLife) About PM360 PM360 is the premier, must-read magazine for marketing decision makers in the pharmaceutical, biotech, diagnostics, and medical device industries. Published monthly, PM360 is the only journal that focuses on delivering the full spectrum of practical information necessary for product managers and pharmaceutical marketing professionals to succeed in the complex and highly regulated healthcare environment. The journal's targeted and insightful editorial focuses on issues that directly impact critical decision making, including: Planning and implementation of cutting-edge strategies, trends, the latest technological advances, branding/marketing, advertising/promotion, patient/professional education, sales, market research, PR, and leadership. Additionally, the "360" in the title signifies the span of this critical, how-to info with personal and career insights for an enjoyable and thought-provoking read. By providing the full circle of enriching content, PM360 is truly an indispensable tool for busy and productive marketing professionals to stay at the top of their game. Contact: Gabrielle Smith Associate Editor, PM360 646-300-8113 [email protected] Gabriela L. Laracca Associate Editor, PM360 646-300-8114 [email protected] SOURCE PM360 WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

疫苗高管变更

100 项与 Corcept Therapeutics, Inc. 相关的药物交易

登录后查看更多信息

100 项与 Corcept Therapeutics, Inc. 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

或

查看完整样例数据

管线布局

2024年11月05日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

药物发现

临床1期

临床2期

临床3期

批准上市

其他

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

Relacorilant ( GR )	腹膜癌更多	临床3期
Dazucorilant ( GR )	肌萎缩侧索硬化更多	临床2期
CORT-125281 ( GR )	转移性去势抵抗性前列腺癌更多	临床1/2期
CORT-122928 ( GR )	前列腺癌更多	临床1期
CORT-125385 ( GR )	非酒精性脂肪性肝炎更多	药物发现